Evidence map›Paper›PMID 40197984›Full record

ArticleEuropean journal of clinical investigation2025

Total lesion glycolysis is a promising predictor of chemo-response in pancreatic cancer patients treated with neoadjuvant chemotherapy prior to surgery.

Sooin Byeon, Bridget Abbott, Paul Roach, Dale L Bailey, Angela Chou, Sarah Maloney, Anthony J Gill, Jaswinder Samra, Anubhav Mittal, Sumit Sahni

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sooin ByeonNorthern Clinical School, Faculty of Medicine and Health, University of Sydney, St Leonards, New South Wales, Australia.
Bridget AbbottDepartment of Nuclear Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Paul RoachDepartment of Nuclear Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Dale L BaileyNorthern Clinical School, Faculty of Medicine and Health, University of Sydney, St Leonards, New South Wales, Australia.
Angela ChouNorthern Clinical School, Faculty of Medicine and Health, University of Sydney, St Leonards, New South Wales, Australia.
Sarah MaloneyNorthern Clinical School, Faculty of Medicine and Health, University of Sydney, St Leonards, New South Wales, Australia.
Anthony J GillNorthern Clinical School, Faculty of Medicine and Health, University of Sydney, St Leonards, New South Wales, Australia.
Jaswinder SamraAustralian Pancreatic Centre, St Leonards, Sydney, New South Wales, Australia.
Anubhav MittalNorthern Clinical School, Faculty of Medicine and Health, University of Sydney, St Leonards, New South Wales, Australia.
Sumit SahniNorthern Clinical School, Faculty of Medicine and Health, University of Sydney, St Leonards, New South Wales, Australia.ORCID https://orcid.org/0000-0002-2900-8845

Funding

Philanthropic Donations
6 · The paper itself

Abstract

backgroundThere has been increased use of neoadjuvant chemotherapy (NAC) in resectable pancreatic ductal adenocarcinoma (PDAC) patients. [

methodsIn this single centre, retrospective study, NAC-treated PDAC patients (n = 74) for whom both pre- and post-NAC FDG-PET/CT scans were available were recruited. All scans were imported to a single analysis platform and reanalysed. Chemo-response was determined by the assessment of percentage viable tumour cells in the tumour bed. Statistical analysis was performed on the data.

resultsA significant correlation was observed between post-treatment FDG-PET/CT scan parameters and viable cancer cells in the tumour bed, with TLG showing a higher degree of correlation (r = .3131) compared to all other parameters (r = .2722-.3008). The percentage decrease in the TLG (post-NAC scan vs. pre-NAC scan) demonstrated the highest degree of correlation with viable cancer cells in the tumour bed (r = -.3444) and had a statistically significant (p = .0157) effect between NAC responders (Median = 80.57) and non-responders (Median = 65.16). The difference between TLG (post-NAC scan vs. pre-NAC scan) was shown to be an independent prognostic indicator for overall survival (hazard ratio = .5033, p = .0361).

conclusionTLG was shown to be a superior predictor of chemo-response and patient prognosis compared to all other FDG-PET/CT parameters in PDAC patients treated with NAC.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalGlycolysisPancreatic NeoplasmsAdultAgedChemotherapy, AdjuvantFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedNeoadjuvant TherapyPositron Emission Tomography Computed TomographyRadiopharmaceuticalsRetrospective StudiesFluorodeoxyglucose F18Radiopharmaceuticalsimaging biomarkerspancreatic ductal adenocarcinomaPET scanSUVmaxtotal lesion glycolysis

Identifiers

PMID40197984
PMCPMC12362050

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.